The aim of pharmaceutical development is to design a qualityproduct an的简体中文翻译

The aim of pharmaceutical developme

The aim of pharmaceutical development is to design a qualityproduct and its manufacturing process to consistently deliver theintended performance of the product. Many new regulatory initiativeswere introduced in the last decade e.g. Pharmaceutical GoodManufacturing Process (GMP) for 21st Century,1 Quality by Design(QbD).2 Process Analytical Technology (PAT)3 and Quality Systeminitiative.4 All these approaches provide a better understanding of theproducts. Since pharmaceutical development takes approximately 10years with a cost of close to a billion dollars, a tool is required thatprovides a structured plan. Such a tool is known as Target ProductProfile (TPP).5–7 It is simply a planning tool in the development stageof Pharmaceutical R&D process, in which a drug candidate fromdiscovery is subjected to clinical development to determine safety,efficacy, and marketing suitability. This concept was originated in1997 through discussions between FDA and a Clinical Developmentworking group for improving sponsor and FDA interactions.5,6 Theworking committee recommended the use of a “template” thatsummarizes a drug labeling concept to help focus discussions and aidin the understanding between sponsors and the FDA.7 The outcome ofthe discussions resulted in minimization of the risk of late stage drugdevelopment process, increasing the probability of obtaining optionalsafety and efficacy data in a timely manner, improving labeling contentand possible minimization of time involved in drug development.7
0/5000
源语言: -
目标语言: -
结果 (简体中文) 1: [复制]
复制成功!
药物开发的目的是设计高质量的<br>产品及其制造过程,以始终如一地提供<br>产品预期的性能。<br>在过去的十年中,引入了许多新的监管举措,例如<br>21世纪的药品良好生产过程(GMP),1 <br>设计质量<br>(QbD)。2 <br>过程分析技术(PAT)3 <br>和质量体系<br>举措。4 <br>所有这些方法都提供了更好的方法。对<br>产品的了解。由于药物开发需要大约10 <br>年的时间,成本接近10 亿美元,因此需要一种工具来<br>提供结构化计划。这样的工具被称为目标产品<br>Profile(TPP).5–7只是<br>药物研发过程开发阶段的一种计划工具,其中对<br>发现的候选药物进行临床开发以确定安全性,<br>功效和市场适用性。这个概念起源于<br>通过FDA和临床开发的讨论1997年<br>为提高赞助商,FDA工作组interactions.5,6的<br>工作委员会建议使用一个“模板”的<br>总结药品打标概念,有助于集中讨论和援助<br>在赞助商和FDA.7之间的了解<br>的结果<br>的讨论导致后期药物的风险最小化<br>开发过程中,增加<br>及时获得可选的安全性和功效数据的可能性,提高标签含量<br>并尽可能减少药物开发所需的时间7。
正在翻译中..
结果 (简体中文) 2:[复制]
复制成功!
The aim of pharmaceutical development is to design a quality<br>product and its manufacturing process to consistently deliver the<br>intended performance of the product. Many new regulatory initiatives<br>were introduced in the last decade e.g. Pharmaceutical Good<br>Manufacturing Process (GMP) for 21st Century,1<br> Quality by Design<br>(QbD).2<br> Process Analytical Technology (PAT)3<br> and Quality System<br>initiative.4<br> All these approaches provide a better understanding of the<br>products. Since pharmaceutical development takes approximately 10<br>years with a cost of close to a billion dollars, a tool is required that<br>provides a structured plan. Such a tool is known as Target Product<br>Profile (TPP).5–7 It is simply a planning tool in the development stage<br>of Pharmaceutical R&D process, in which a drug candidate from<br>discovery is subjected to clinical development to determine safety,<br>efficacy, and marketing suitability. This concept was originated in<br>1997 through discussions between FDA and a Clinical Development<br>working group for improving sponsor and FDA interactions.5,6 The<br>working committee recommended the use of a “template” that<br>summarizes a drug labeling concept to help focus discussions and aid<br>in the understanding between sponsors and the FDA.7<br> The outcome of<br>the discussions resulted in minimization of the risk of late stage drug<br>development process, increasing the probability of obtaining optional<br>safety and efficacy data in a timely manner, improving labeling content<br>and possible minimization of time involved in drug development.7
正在翻译中..
结果 (简体中文) 3:[复制]
复制成功!
药物开发的目的是设计一种质量<br>产品及其制造过程,以持续交付<br>产品的预期性能。许多新的监管举措<br>是在过去十年中引入的,例如药品<br>21世纪的生产工艺(GMP),1<br>设计质量<br>(问题)。2<br>过程分析技术(PAT)3<br>和质量体系<br>主动性。4<br>所有这些方法都可以更好地理解<br>产品。因为药物开发大约需要10年<br>花费近10亿美元的年,需要一个工具<br>提供结构化计划。这种工具被称为目标产品<br>简介(TPP)。5–7它只是开发阶段的一个规划工具<br>药物研发过程中<br>这一发现需要经过临床研究以确定其安全性,<br>有效性和市场适宜性。这个概念起源于<br>1997年通过FDA和临床研究的讨论<br>改善赞助人与食品和药物管理局相互作用工作组<br>工作委员会建议使用<br>总结药物标签的概念,以帮助集中讨论和帮助<br>在赞助者和FDA之间的理解中<br>结果<br>讨论的结果是使晚期药物的风险最小化<br>开发过程中,增加了获得可选的可能性<br>及时提供安全性和有效性数据,提高标签内容<br>以及尽可能缩短药物研发的时间<br>
正在翻译中..
 
其它语言
本翻译工具支持: 世界语, 丹麦语, 乌克兰语, 乌兹别克语, 乌尔都语, 亚美尼亚语, 伊博语, 俄语, 保加利亚语, 信德语, 修纳语, 僧伽罗语, 克林贡语, 克罗地亚语, 冰岛语, 加利西亚语, 加泰罗尼亚语, 匈牙利语, 南非祖鲁语, 南非科萨语, 卡纳达语, 卢旺达语, 卢森堡语, 印地语, 印尼巽他语, 印尼爪哇语, 印尼语, 古吉拉特语, 吉尔吉斯语, 哈萨克语, 土库曼语, 土耳其语, 塔吉克语, 塞尔维亚语, 塞索托语, 夏威夷语, 奥利亚语, 威尔士语, 孟加拉语, 宿务语, 尼泊尔语, 巴斯克语, 布尔语(南非荷兰语), 希伯来语, 希腊语, 库尔德语, 弗里西语, 德语, 意大利语, 意第绪语, 拉丁语, 拉脱维亚语, 挪威语, 捷克语, 斯洛伐克语, 斯洛文尼亚语, 斯瓦希里语, 旁遮普语, 日语, 普什图语, 格鲁吉亚语, 毛利语, 法语, 波兰语, 波斯尼亚语, 波斯语, 泰卢固语, 泰米尔语, 泰语, 海地克里奥尔语, 爱尔兰语, 爱沙尼亚语, 瑞典语, 白俄罗斯语, 科西嘉语, 立陶宛语, 简体中文, 索马里语, 繁体中文, 约鲁巴语, 维吾尔语, 缅甸语, 罗马尼亚语, 老挝语, 自动识别, 芬兰语, 苏格兰盖尔语, 苗语, 英语, 荷兰语, 菲律宾语, 萨摩亚语, 葡萄牙语, 蒙古语, 西班牙语, 豪萨语, 越南语, 阿塞拜疆语, 阿姆哈拉语, 阿尔巴尼亚语, 阿拉伯语, 鞑靼语, 韩语, 马其顿语, 马尔加什语, 马拉地语, 马拉雅拉姆语, 马来语, 马耳他语, 高棉语, 齐切瓦语, 等语言的翻译.

Copyright ©2024 I Love Translation. All reserved.

E-mail: